News

Filter

Current filters:

Lexiscan

CV's 3rd-qtr 2008 loss narrows 26% to $25.4M

17-11-2008

US drugmaker CV Therapeutics' third-quarter 2008 net loss narrowed 25.7% on the comparable period the…

Amino AcidsInjectionLexiscanMenariniPhysostigmine SalicylateRanexaRanolazineRegadenoson Injection

Lexiscan launch earns CV $10M milestone

30-06-2008

The launch of Lexiscan by the US unit of Japanese drug major Astellas has earned CV Therapeutics a milestone…

AdenocardAdenosineAmino AcidsInjectionLexiscanPhysostigmine SalicylateRegadenoson Injection

FDA approval for CV and Astellas' Lexiscan

28-04-2008

USA-based CardioVascular BioTherapeutics and the US arm of Japanese drug major Astellas have received…

AdenocardAdenosineAmino AcidsInjectionLexiscanPhysostigmine SalicylateRegadenoson Injection

COMPANY SPOTLIGHT

Menarini

Back to top